BIIB Biogen Inc. Common Stock BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) Best Biotech Stocks 2026 →

Biogen (BIIB) Stock: Buy, Sell, or Hold?

$253.94
+0.54 (+0.21%) ▲
5d: -0.36% 30d: +9.15% 90d: +19.47%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (71%)
Quality Score
50/100
Position
SLIGHTLY HIGH
30-Day Fair Range
$234.02 – $254.67
Position: SLIGHTLY HIGH
Forward P/E & Valuation
15.6x STRETCHED
vs 12.3x historical avg
Wall Street Target
$268.26
+5.9% upside
Options IV & Volume
5th pct IV
HIGH volume confirmation
Support / Resistance
$240.00 / $261.00
Trend: Strong Uptrend
💡Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
â„šī¸ NEUTRAL: BIIB is fairly priced but lacks strong directional signals. At 8.1% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.

Get Alerted When BIIB Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$389.44
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$241.81
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.3x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: BIIB is currently trading at $253.94, which is considered slightly high relative to its 30-day fair value range of $234.02 to $254.67. From a valuation perspective, the stock is trading at a premium (Forward PE: 15.6) compared to its historical average (12.3). At these levels, the market is pricing in 8.1% annual earnings growth.

Technical Outlook: Technically, BIIB is in a strong uptrend. The price is approaching resistance at $261.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position SLIGHTLY HIGH
Historical Trading Range $234.02 - $254.67
Company Quality Score 50/100 (HOLD)
Options IV Signal 5th percentile (LOW)
Volume Confirmation HIGH
Confidence Score 70.8%

Trading Range & Key Levels

30-Day Trading Range $234.02 - $254.67
Current vs Trading Range SLIGHTLY HIGH
Expected Move (7 Days) Âą$18.73 (7.4%)
Support Level $240.00
Resistance Level $261.00
Current Trend Strong Uptrend
Technical data as of Nov 16, 2026

Protect Your Profits

Holding BIIB? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

Institutional Signals, 13F Whale Activity & Setup Structure

Quantitative Research Feed
Phase & Gamma Walls CONSOLIDATION
Days in Phase: 17d (70% conf)
Put Wall / Support: $230 (1,869 OI)
Call Wall / Resist: $255 (2,263 OI)
Technical Setup Structure MONITORING
Absorption: Inactive (CMF 0.04)
Pullback / Drawdown: -0.6% from 52W High
Consolidation: Trending (ADX 28.7)
30D Insider Cluster Signal TRACKED
30D Insider Buyers: 0 insiders ($0)
30D Net Insider Flow: $-239,750

Quantitative Signal Breakdown

  • BULLISH: Options cheap (IV 5th percentile)
  • NEUTRAL: Mixed technical signals (45/100)
  • BULLISH: High volume confirmation
  • NEUTRAL: Near Wall St target ($268.26)
  • BULLISH: Expecting earnings turnaround to 8.1% growth with 10.6% revenue growth
  • WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market

Fundamental Context

Forward P/E (Next Year Est.) 15.59
Wall Street Target $268.26 (+5.9%)
Revenue Growth (YoY) 10.6%
Earnings Growth (YoY) -84.8%
Profit Margin 3.4%
Valuation Premium vs History +8.1% premium
PE vs Historical 15.6 vs 12.3 STRETCHED
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +8.1% (market-implied from PE analysis)
1-Year Target $273.93 (+8%)
2-Year Target $296.11 (+17%)
3-Year Target $320.10 (+26%)
3-Yr Target (if PE normalizes) (PE: 16→12) PE COMPRESSION $252.62 (0%)
Earnings growth offset by PE compression
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 19.9, Growth: 29.7%) $704.83 (+178%)
Base: (SPY PE: 15.6, Growth: 29.7%) $553.13 (+118%)
Bear: (PE: 12.3, Growth: 29.7%) $436.53 (+72%)
📈 Valuation based on Current Earnings
Forward PE: 16.39 | Forward EPS (Implied): $15.46
Bull Case $305.98 (+21%)
Analyst growth 15.0%, PE expands to 17.2
Base Case $253.40 (0%)
Market implied 0.0%, PE stable at 16.4
Bear Case $193.85 (-24%)
Severe decline -15.0%, PE contracts to 14.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share BIIB Analysis

Share this live BIIB analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

bloggers & journalists: you are free to use our charts with attribution.

Reddit & Retail Trader Sentiment (BIIB)

Bullish 2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Sep 29, 2026
Daily AI digest
AI Retail Discussion Summary: Biogen's growth portfolio surpassed revenues from its legacy MS drugs in Q2 2026, driven by Skyclarys, Zurzuvae, Spinraza, and Leqembi.
Key Retail Themes: Biogen's revenue mix shift Growth portfolio performance
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams. View All Trending Reddit & WSB Stocks →
Last updated: November 16, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
đŸ”Ĩ Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for BIIB.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
ABBV
AbbVie Inc
STRONG BUY
29 analysts
$312 52 HOLD
MRK
Merck & Company Inc
BUY
28 analysts
$162 64 BUY
LLY
Eli Lilly and Company
STRONG BUY
31 analysts
$1463 40 HOLD
GILD
Gilead Sciences Inc
STRONG BUY
28 analysts
$175 47 HOLD
JNJ
Johnson & Johnson
BUY
23 analysts
$279 47 HOLD

Advanced BIIB Option Strategies

Professional options setups generated by AI based on today's BIIB price and gamma walls.

Iron Condor Bull Call Bear Put Collar
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals